Cargando…

Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome

BACKGROUND: To investigate the prognostic significance of disseminated tumor cells (DTCs) in bone marrow (BM) from non-metastatic breast cancer patients before and after surgery. METHODS: Patients with non-metastatic breast cancer were consecutively recruited to this project during the years 1998–20...

Descripción completa

Detalles Bibliográficos
Autores principales: Tjensvoll, Kjersti, Oltedal, Satu, Heikkilä, Reino, Kvaløy, Jan Terje, Gilje, Bjørnar, Reuben, James M, Smaaland, Rune, Nordgård, Oddmund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443029/
https://www.ncbi.nlm.nih.gov/pubmed/22640166
http://dx.doi.org/10.1186/1471-2407-12-190
_version_ 1782243504810885120
author Tjensvoll, Kjersti
Oltedal, Satu
Heikkilä, Reino
Kvaløy, Jan Terje
Gilje, Bjørnar
Reuben, James M
Smaaland, Rune
Nordgård, Oddmund
author_facet Tjensvoll, Kjersti
Oltedal, Satu
Heikkilä, Reino
Kvaløy, Jan Terje
Gilje, Bjørnar
Reuben, James M
Smaaland, Rune
Nordgård, Oddmund
author_sort Tjensvoll, Kjersti
collection PubMed
description BACKGROUND: To investigate the prognostic significance of disseminated tumor cells (DTCs) in bone marrow (BM) from non-metastatic breast cancer patients before and after surgery. METHODS: Patients with non-metastatic breast cancer were consecutively recruited to this project during the years 1998–2000. Real-time RT-PCR quantification of a DTC multimarker panel consisting of cytokeratin 19, mammaglobin A and TWIST1 mRNA was performed in BM samples obtained from 154 patients three weeks (BM2) and/or six months after surgery (BM3). The results were compared to previously published data from pre-operative BM analyses for the same patients. RESULTS: DTCs were identified in post-operative BM samples (BM2 and/or BM3) from 23 (15%) of the 154 patients investigated. During a median follow-up of 98 months, 10 (44%) of these patients experienced systemic relapse as compared to 16 (12%) of 131 DTC-negative patients. Kaplan-Meier estimates of systemic recurrence-free- and breast-cancer specific survival demonstrated significantly shorter survival for patients with persistent DTCs in BM after surgery (p≤0.001). By multivariate Cox regression analyses, persistent DTCs after surgery was an independent predictor of both systemic recurrence-free- (HR = 5.4, p < 0.001) and breast-cancer specific survival (HR = 5.3, p < 0.001). Furthermore, the prognostic value of DTCs in BM was similar for pre- and post surgery samples. However, patients with DTCs both before and after surgery (BM1 and BM2/3) had a particularly poor prognosis (systemic recurrence-free survival: HR = 7.2, p < 0.0001 and breast-cancer specific survival: HR = 8.0, p < 0.0001). CONCLUSIONS: Detection of persistent DTCs in BM samples obtained after surgery identified non-metastatic breast cancer patients at high risk for systemic relapse, and with reduced breast-cancer specific survival. Furthermore, patients with positive DTC status both before and after surgery had a particularly poor prognosis.
format Online
Article
Text
id pubmed-3443029
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34430292012-09-15 Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome Tjensvoll, Kjersti Oltedal, Satu Heikkilä, Reino Kvaløy, Jan Terje Gilje, Bjørnar Reuben, James M Smaaland, Rune Nordgård, Oddmund BMC Cancer Research Article BACKGROUND: To investigate the prognostic significance of disseminated tumor cells (DTCs) in bone marrow (BM) from non-metastatic breast cancer patients before and after surgery. METHODS: Patients with non-metastatic breast cancer were consecutively recruited to this project during the years 1998–2000. Real-time RT-PCR quantification of a DTC multimarker panel consisting of cytokeratin 19, mammaglobin A and TWIST1 mRNA was performed in BM samples obtained from 154 patients three weeks (BM2) and/or six months after surgery (BM3). The results were compared to previously published data from pre-operative BM analyses for the same patients. RESULTS: DTCs were identified in post-operative BM samples (BM2 and/or BM3) from 23 (15%) of the 154 patients investigated. During a median follow-up of 98 months, 10 (44%) of these patients experienced systemic relapse as compared to 16 (12%) of 131 DTC-negative patients. Kaplan-Meier estimates of systemic recurrence-free- and breast-cancer specific survival demonstrated significantly shorter survival for patients with persistent DTCs in BM after surgery (p≤0.001). By multivariate Cox regression analyses, persistent DTCs after surgery was an independent predictor of both systemic recurrence-free- (HR = 5.4, p < 0.001) and breast-cancer specific survival (HR = 5.3, p < 0.001). Furthermore, the prognostic value of DTCs in BM was similar for pre- and post surgery samples. However, patients with DTCs both before and after surgery (BM1 and BM2/3) had a particularly poor prognosis (systemic recurrence-free survival: HR = 7.2, p < 0.0001 and breast-cancer specific survival: HR = 8.0, p < 0.0001). CONCLUSIONS: Detection of persistent DTCs in BM samples obtained after surgery identified non-metastatic breast cancer patients at high risk for systemic relapse, and with reduced breast-cancer specific survival. Furthermore, patients with positive DTC status both before and after surgery had a particularly poor prognosis. BioMed Central 2012-05-28 /pmc/articles/PMC3443029/ /pubmed/22640166 http://dx.doi.org/10.1186/1471-2407-12-190 Text en Copyright ©2012 Tjensvoll et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tjensvoll, Kjersti
Oltedal, Satu
Heikkilä, Reino
Kvaløy, Jan Terje
Gilje, Bjørnar
Reuben, James M
Smaaland, Rune
Nordgård, Oddmund
Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
title Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
title_full Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
title_fullStr Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
title_full_unstemmed Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
title_short Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
title_sort persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443029/
https://www.ncbi.nlm.nih.gov/pubmed/22640166
http://dx.doi.org/10.1186/1471-2407-12-190
work_keys_str_mv AT tjensvollkjersti persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome
AT oltedalsatu persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome
AT heikkilareino persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome
AT kvaløyjanterje persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome
AT giljebjørnar persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome
AT reubenjamesm persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome
AT smaalandrune persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome
AT nordgardoddmund persistenttumorcellsinbonemarrowofnonmetastaticbreastcancerpatientsafterprimarysurgeryareassociatedwithinferioroutcome